Navigation Links
Poniard Pharmaceuticals Announces Upcoming Conference Participation
Date:2/4/2008

SOUTH SAN FRANCISCO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that Jerry McMahon, Ph.D., chairman and CEO, will present at the 10th Annual BIO CEO & Investor Conference 2008 on Monday, February 11, at 11:45 a.m. Eastern Time at the Waldorf-Astoria in New York.

Dr. McMahon will provide a corporate overview, including a discussion of the clinical development program for picoplatin, the Company's lead product candidate.

A live audio webcast of the presentation will be available for 10 business days on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile compared to currently available platinum-based therapies. Picoplatin is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone-refractory prostate cancers. For additional information please visit http://www.poniard.com.

(C) 2008 Poniard Pharmaceuticals, Inc. All Rights Reserved. Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... , ... TopConsumerReviews.com recently gave a best-in-class 5 star rating to SpinLife, a ... to people who need help getting around. For some, advancing age has led to ... rehabilitation after an illness or accident. There is a wide variety of scooters, from ...
(Date:12/6/2016)... California (PRWEB) , ... December 06, 2016 , ... "Add ... users to flicker, flash, and flare from clip to clip with high quality 4K ... , TransFlare 4K Jewel contains 44 lens flares filmed on the RED Dragon. Utilizing ...
(Date:12/5/2016)... ... 05, 2016 , ... What: Shriners Hospitals for Children, with the help of ... – using a video monitor and web-enabled camera. Santa visits with children through Dimension ... a Christmas Wonderland, which is where the video connection to the North Pole will ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... Surgery, is excited to announce the arrival of the newest Sciton laser in ... the ability to use tunable non-ablative and ablative wavelengths for exceptional results. Outperforming ...
(Date:12/5/2016)... , ... December 06, 2016 , ... For many years, ... poetry , both thick and thin. The beauty of the Lithuanian language ... Publishing). , In this poetry book, Zubinas lyrically explores all aspects of a living, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... R.I. , Dec. 5, 2016  CVS Health, ... it has received a perfect score of 100 percent ... consecutive year. The CEI is an annual national benchmarking ... to LGBT equality, administered by the Human Rights Campaign ... the rich diversity that our colleagues, customers and suppliers ...
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 ... today announced preliminary safety and efficacy data from ... oral selective MDM2 inhibitor, suggesting that DS-3032 may ... relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic ... part of the phase 1 study of DS-3032 were ...
(Date:12/5/2016)... -- John Seng, founder of Spectrum Science Communications , announced today ... Officer following two consecutive years of high double digit growth in ... 2014 and assumed management of the firm that Seng founded in ... Healthcare Agency of the Year and was selected among the Best ... ...
Breaking Medicine Technology: